All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets

By Public Technologies
  • Ocugen granted Celairis exclusive commercialization rights to investigational retinitis pigmentosa gene therapy OCU400 in Australia, New Zealand and ASEAN markets.
  • License fees and potential milestones total up to $7.1 million, including $6.1 million tied to upfront payment and top-line results.
  • The deal also provides a high single-digit royalty on net sales and 50% of regional gross profits from OCU400 net sales.
  • Celairis will handle regional regulatory submissions, market access and commercialization; a planned supply agreement would cover manufacturing by the developer.
  • Phase 3 top-line results are expected in the first quarter of 2027, with regional regulatory submissions expected following planned global filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874088) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.